MedTrace Logo

Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.

NCT03436212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-16

No results posted yet for this study

Summary

This study aims at describing the glucose level by automated glucose sensors and correlating it with insulin delivery and meals over 14 days in insulin-requiring T2D patients living in real-life conditions.

Conditions

Interventions

DEVICE

Continuous Glucose Monitoring (CGM)

DEXCOMG4 device

Sponsors & Collaborators

  • Air Liquide Santé International

    lead INDUSTRY

Principal Investigators

  • Yves Reznik, MD · CHU CAEN

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2018-03-06
Completion
2018-03-06

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436212 on ClinicalTrials.gov